Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Drugmaker Perrigo to Buy Irish Elan for USD 8.6 Billion

By BiotechDaily International staff writers
Posted on 05 Aug 2013
Perrigo (Allegan, MI, USA), the largest manufacturer of private label over-the-counter (OTC) pharmaceuticals in the United States, has agreed to buy Elan (Dublin, Ireland).

Perrigo and Elan will be combined under the umbrella of New Perrigo, a company recently incorporated in Ireland. New Perrigo, which is expected to be called Perrigo Company, will be led by Perrigo’s current leadership team, headed by Joseph C. Papa, chairman and CEO of the company. Immediately after the closing of the transaction, Perrigo shareholders are expected to receive approximately 71% of the combined company, while Elan shareholders are expected to own approximately 29%.

The amalgamation of the companies is expected to result in more than USD 150 million of recurring after-tax annual operating expense and tax savings as a result of the combined company being incorporated in Ireland with organizational, operations, and capitalization structures that will enable it to more efficiently manage global cash and treasury operations. Some of these synergies will result from the elimination of redundant public company costs, while optimizing back-office support and the global R&D functions.

However, the major advantage for Perrigo is that the deal will allow it to move corporate headquarters to Ireland, where it will enjoy a low 12.5% corporate tax rate, compared to 35% in the United States. The move will also give Perrigo a gateway to the rest of Europe, as well as generating a healthy income from Elans’ remaining 50% interest in royalties from the sales of multiple sclerosis (MS) drug Tysabri. Elan sold its 50% interest in Tysabri to US partner Biogen Idec (Weston, MA, USA; www.biogenidec.com) in February 2013 for USD 3.25 billion, but retained some royalties in the drug, whose sales rose to USD 1.6 billion in 2012.

“We believe this transaction is compelling for Elan shareholders and fully takes into account the value of Elan’s assets, including a large cash balance and a double-digit royalty claim on Tysabri,” said Joe Papa. “We believe the combination of Perrigo and Elan will create an industry-leading global healthcare company with the balance sheet liquidity and operational structure to accelerate our growth and capitalize on international market opportunities.”

“The Elan platform has been constructed over the years to provide a unique and compelling investment thesis for our shareholders,” said Kelly Martin, CEO of Elan. “This transaction underscores the tremendous value of Elan's platform. The new combined company should deliver value, growth and diversification to shareholders for many years to come.”

The acquisition ends a prolonged takeover battle during which Elan rejected three lower bids from US investment firm Royalty Pharma amid injunctions, court hearings, and a verbal slinging match before putting itself up for sale in June 2013.


Related Links:

Perrigo
Elan
Biogen Idec




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.